Shares of Sandoz Group AG (OTCMKTS:SDZNY - Get Free Report) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $48.66 and last traded at $48.61, with a volume of 114786 shares traded. The stock had previously closed at $46.70.
Analysts Set New Price Targets
Several research firms recently commented on SDZNY. UBS Group cut shares of Sandoz Group from a "strong-buy" rating to a "hold" rating in a research report on Monday, February 3rd. BNP Paribas downgraded Sandoz Group from a "strong-buy" rating to a "hold" rating in a research note on Monday, December 2nd.
Read Our Latest Stock Report on SDZNY
Sandoz Group Trading Down 1.0 %
The company's fifty day moving average is $43.63 and its 200 day moving average is $43.30.
Sandoz Group Company Profile
(
Get Free Report)
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.
Read More
Before you consider Sandoz Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sandoz Group wasn't on the list.
While Sandoz Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
